Polymyxin Co-Formulation with Polyaspartic Acid for Pulmonary Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inhaled polymyxins, used to treat pulmonary infections, cause pulmonary toxicities such as eosinophilia, hypersensitivity pneumonitis, and acute respiratory failure due to high doses, and their dosage regimens have not been optimized using pharmacokinetic/pharmacodynamic principles, leading to mitochondrial toxicity and oxidative stress in lung epithelial cells.
Innovation Solution
Co-formulation of polymyxins with polyaspartic acid or polyglutamic acid to reduce toxicity, where the molar ratio of polymyxin to these acids ranges from 1:1 to 1:20, and the use of spray-drying technology to create dry powder compositions for pulmonary delivery, which are administered via inhalation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of inhaled polymyxins are used to treat pulmonary infections, then therapeutic efficacy is improved, but pulmonary toxicity increases
Solution Approach 1:
The patent introduces polyaspartic acid as an intermediary substance that binds to polymyxins, forming a complex that reduces the toxicity of polymyxins while maintaining their antimicrobial activity. This intermediary approach allows high doses of polymyxins to be used effectively against Gram-negative bacteria while preventing the harmful effects such as pulmonary eosinophilia, hypersensitivity pneumonitis, and acute respiratory failure.
Solution Approach 2:
The patent creates a composite formulation combining polymyxins with polyaspartic acid, where the two substances work synergistically. The composite material approach allows the polymyxin-polyaspartic acid complex to exhibit both the desired therapeutic properties and reduced toxicity, resolving the contradiction between efficacy and harm.
2Reliability
If high doses of inhaled polymyxins are used to treat pulmonary infections, then therapeutic efficacy is improved, but mitochondrial toxicity increases
Solution Approach 1:
Polyaspartic acid acts as a mediator that interferes with the interaction between polymyxins and mitochondrial structures. The形成的 complex prevents polymyxins from directly targeting and damaging mitochondria, thereby reducing mitochondrial toxicity while preserving the ability to effectively treat pulmonary infections.
Solution Approach 2:
The patent converts the harmful effect of polymyxin binding to cell membranes (which causes mitochondrial damage) into a beneficial approach by using polyaspartic acid to preemptively bind to polymyxins, redirecting their action away from mitochondria and toward the extracellular space where they can still exert antimicrobial effects.
3Reliability
If high doses of inhaled polymyxins are used to treat pulmonary infections, then therapeutic efficacy is improved, but oxidative stress increases
Solution Approach 1:
Polyaspartic acid serves as a protective intermediary that prevents polymyxins from inducing oxidative stress in lung epithelial cells. The formed complex blocks the polymyxin-induced production of reactive oxygen species and prevents the activation of pro-oxidant signaling pathways, thereby maintaining therapeutic efficacy while eliminating oxidative stress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces polymyxin-induced toxicity in lung epithelial cells and tissues, as demonstrated by increased cell viability, reduced mitochondrial superoxide formation, and improved mitochondrial membrane potential, with effective attenuation of lung damage in animal models, while maintaining optimal aerosolization properties for inhalation.
Implementation Method 1
Co-formulation of polymyxins with polyaspartic acid or polyglutamic acid to reduce toxicity
Implementation Method 2
the use of spray-drying technology to create dry powder compositions for pulmonary delivery
Data Source
AI summary
The present disclosure generally relates to a method for reducing the toxicity of polymyxins as a therapeutic agent comprising the step of coadministration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.